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tients and 62 peritoneal-dialysis patients at Siriraj hospital. Utility scores and the
correlation coefficientwith KDQOL-36were calculated. Percentages of respondents
with the ceiling and floor effects were compared for each of the different measure-
ment tools. RESULTS: Patient samples had a mean age of 60.2014.84 years. Mean
duration of dialysis were 7.445.42 years for hemodialysis patients, and 1.821.22
years for peritoneal-dialysis patients. The mean SF-6D score (0.7830.164) was
significantly higher than EQ-5D (UK: 0.7520.309, Thai: 0.6910.314), and VAS
(0.6660.196) scores. Most of the kidney specific dimensions were better correlated
with SF-6D than EQ-5D (UK and Thai preference weight) and VAS scores. Ceiling
effects were observed in the EQ-5D concerning both UK and Thai preference
weight, due to the fact that the EQ-5D differentiates less in the better health states,
whereas the floor effects were not clearly observed in any instrument tools.
CONCLUSIONS: SF-6D presented better correlation with kidney specific scales
while the responsiveness of EQ-5D utility scores was poor. One explanation might
be a ‘‘ceiling effect’’ of the EQ-5D. These findings implied that SF-6D utility scores
could reflect HRQoL status of dialysis patients better than EQ-5D and VAS.
PUK36
USING BOOTSTRAP CONFIDENCE INTERVALS TO COMPARE RELATIVE
VALIDITY COEFFICIENTS: AN EXAMPLE WITH PRO MEASURES OF CHRONIC
KIDNEY DISEASE (CKD) IMPACT
Deng N, Ware J
University of Massachusetts Medical School, Worcester, MA, USA
OBJECTIVES: To evaluate bootstrap techniques in comparing the validity of PRO
measures in discriminating among CKD patients and responding to longitudinal
changes.METHODS: The Kidney Disease Impact Scale (KDIS), CKD-specific legacy
(KDQOL Burden, Symptom, and Effect) and generic health (SF-12) scales were ad-
ministrated to 453 patients and re-administered to 110 patients after threemonths.
ANOVA-based relative validity (RV) coefficients were used to compare how well
each scale discriminated between three clinically-defined groups ordered in terms
of severity (Dialysis Stage 3-5 Transplant), and how responsive each scale was
to changes over time for self-evaluated Better, Same and Worse groups. Bootstrap
was used to construct confidence intervals (CIs) to determine whether the differ-
ences in RVs were significant in comparisons between each scale and the best
legacy measure - KDQOL Burden. Sample size, number of bootstrap iterations, and
type of CIs were varied to evaluate their impacts on CI using real and artificial data.
RESULTS: The sample size played a substantial role. 300 people for 3 groups were
suggested as theminimumnumber tomakemeaningful comparisons betweenRVs
using CI. Number of bootstrap replications (100 to 10,000) did not show an obvious
effect on bootstrap standard error, although 300 showed improvement over 100 on
CI. The bias-corrected and accelerated (BCa) type of CI was preferred for correcting
both bias and skewness in bootstrap distribution and for producing narrower CIs.
Using 95% CI and 300 sample size, differences in RVs were non-significant in com-
parisonswith KDQOL-Burden (RV1) for the following scales: SF-12 PCS (RV.6), PF
(RV.7), RP (RV .77), KDQOL-Effect (RV.99), and KDIS (RV1.13). CONCLUSIONS:
Bootstrapping appears to be valuable in testing the significance of differences in
the relative validity of these PRO measures from a statistical perspective. Samples
of 100 per group compared and 300 bootstrap replications are recommended.
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COMPLIANCE ON THE CONSOLIDATED STANDARDS OF REPORTING TRIALS
(CONSORT) GUIDELINES IN RANDOMIZED CONTROLLED TRIALS
Godwin OP1, Dyson B1, Park SY1, Lee E2
1Howard University Center for Minority Health Services Research, College of Pharmacy,
Washington, DC, USA, 2Howard University, Washington, DC, USA
OBJECTIVES: The Consolidated Standards of Reporting Trials (CONSORT) state-
mentwas published in 2001 and updated in 2010, strongly recommended the use of
CONSORT diagram to report the flow of participants through each stages of the
trial. This studywas conducted to describe the level of compliance of the published
clinical trial in following the CONSORT recommendations and to estimate preva-
lence of the compliance.METHODS: A systematic literature search of all random-
ized controlled trials of anti-infectious agents published in the top 10 general med-
icine journals and top 5 infectious disease journals published in 2010. The journals
include: The New England Journal of Medicine, Journal of the American Medical
Association, British Medical Journal (Clinical Research Ed), Archives of Internal
Medicine, PloS Medicine, Annals of Internal Medicine, Clinical Infectious Diseases,
the Journal of Infectious Diseases, the Lancet Infectious Diseases, AIDS, Emerging
Infectious Diseases Journal, Annual Review of Medicine, Canadian Medical Associ-
ation Journal, and Annals of Medicine Journal. Each article was reviewed by two
independent investigators based on the reporting criteria recommended by the
CONSORT statement. Exclusion criteria included non-randomized control studies,
and studies not including intervention or control group. RESULTS: The study iden-
tified 129 published articles using explicit criteria on Medline search. A total of 73
randomized controlled trials met the inclusion criteria. Of 73 studies, 55 (75.34%)
articles included the CONSORT diagram. A comprehensive depiction of the CON-
SORT guidelines will be made and detail descriptions on the compliances will be
presented by journal types during the presentation. CONCLUSIONS: Randomized
controlled trials published in the top 10 general medicine journals and the top 5
infectious diseases journals in 2010 contain significant deficiencies in reporting the
CONSORT flow chart. The clarity and the completeness of a study could be im-
proved if the CONSORT statement is followed as prescribed.
PRM2
NETWORK META-ANALYSIS OF INDIVIDUAL AND AGGREGATE LEVEL DATA
Jansen JP1, Cope S2
1Mapi Consultancy / Tufts University School of Medicine, Boston, MA, USA, 2Mapi Consultancy,
Boston, MA, USA
OBJECTIVES: Network meta-analysis is often performed with aggregate level data
(AD). A challenge with meta-regression models using AD is that the association
between a patient level covariate and relative treatment effects of the compared
interventions at the study level may not reflect the individual level effect-modifi-
cation. In this paper, non-linear network meta-analysis models for combining in-
dividual patient data (IPD) and AD are presented to reduce bias and uncertainty of
treatment effects in the presence of heterogeneity due to patient characteristics.
METHODS: The first method uses the same model form for IPD and AD. With the
second method, the model for AD is obtained by integrating an underlying IPD
model over the joint within-study distribution of covariates. With a simple simu-
lation study the twomodeling approaches are compared. RESULTS:Having IPD for
a subset of studies improves estimation of treatment effects with network meta-
analysis in the presence of patient level heterogeneity and inconsistency. Of the
two proposed non-linear models for combining IPD and AD, the second approach
seems less affected by bias. Additional studies, however, are needed to assess the
value of both methods. CONCLUSIONS: Overall, for network meta-analysis it is
recommended to use IPD when available, rather than treating all studies as AD.
PRM3
THE ENSEMBLE MINIMUM DATASET: A NEW INSTRUMENT TO EXPLORE
HETEROGENEITY OF TREATMENT EFFECT
Brenneman SK1, Brekke L1, Bancroft TJ1, Shen W2, Paczkowski R2, Berger M1, Kaplan SH3,
Greenfield S3, Buesching DP2
1OptumInsight, Eden Prairie, MN, USA, 2Eli Lilly and Company, Inc., Indianapolis, IN, USA,
3University of California Irvine, Irvine, CA, USA
OBJECTIVES: To develop an instrument that identifies patient groups likely to have
differing responses to treatment, we tested candidate measures thought to dis-
criminate differences among patients in 4 disease cohorts: type 2 diabetes (T2D),
knee osteoarthritis (OA), ischemic heart disease (IHD) and heart failure (HF).
METHODS: Eligible patients identified from claims data were sent a survey includ-
ing 17 scales hypothesized to comprise 4 domains (health profile, personality, be-
havior, life context). Proxies for treatment response were patient-reported global
impression of disease severity (PGIS), global impression of improvement (PGII), and
administrative claims health care utilization (HCU). Variability (SD) and internal
consistency (Cronbach’s alpha) of the scales were examined, as was discriminant
validity against strata of PGIS, PGII and HCU. Conceptual overlap, correlations
among scales, and factor loading within and across domains were examined.
Scales with desirable properties were included in the final instrument. Discrimi-
nant validity of proposed domains was analyzed by ANOVA adjusted for age and
gender. Multiple regression models were used to assess the associations between
the proposed domains and outcomes. RESULTS: A total of 723 T2D patients, 682
knee OA patients, 632 IHD patients, and 588 HF patients completed the survey. The
initial instrument was refined to 7 scales across 3 domains. The health profile
domain significantly discriminated 100% of the strata across disease cohorts (each
P0.001). Personality and behavior domains also discriminated strata well (75%
and 50%, respectively). Alone, the health profile significantly discriminated strata
across disease cohorts in multivariate analyses (each P 0.001). In models includ-
ing all 3 domains, the health profile remained the most important contributor.
CONCLUSIONS: The final ENSEMBLE MDS instrument discriminated among pa-
tients with varied diseases; the health profile provided much of the ability to dis-
criminate. Further research is needed to assess the instrument’s potential to pre-
dict health state changes due to trial interventions.
PRM4
ENHANCING THE HEALTH ECONOMIC VALUE OF RETROSPECTIVE AND
PROSPECTIVE REAL-WORLD STUDIES WITH PHARMACOGENOMIC TESTING:
OPPORTUNITIES AND CHALLENGES ASSOCIATED WITH AN INTEGRATED
PERSONALIZED MEDICINE APPROACH
Payne KA1, Frueh FW2, Sohal J3
1United BioSource Corporation, Dorval, QC, Canada, 2Medco Health Solutions, Inc., Franklin
Lakes , NJ, USA, 3United BioSource Corporation, Hammersmith, UK
OBJECTIVES: A better understanding of a patient’s genetic make-up through phar-
macogenomic testing can help achieve improved and more predictable patient
outcomes, often at equal or lower total treatment cost. Stakeholders including
physicians, payers andpatients alike can benefit from real-world data that identify,
a priori, the sub-groups of patients for whom treatments are likely to be more
cost-effective.METHODS: Retrospective and prospective case study designswithin
which pharmacogenomic testing has been integrated are presented. Design pa-
rameters are described and opportunities and challenges alongside strategies for
resolution are delineated. RESULTS: As the genetic make-up of a patient does not
change, pharmacogenomic testing can be done at any point in time andpairedwith
historical and/or newly collected patient level data. Retrospective studies are
highly efficient as they do not require costly longitudinal follow-up, whereas pro-
spective studies including registries offer the opportunity to augment pharmacog-
enomic and other study data with patient and physician reported outcomes not
otherwise available in the medical chart. Main challenges associated with either
approach include optimizing the patient informed consent process, streamlining
the logistics associated with pharmacogenomic testing and storage in the usual
A159V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
care environment, and data analytics. CONCLUSIONS: The integration of pharma-
cogenomic testingwith real-world studies offers an important opportunity to iden-
tify sub-groups of patients for whom treatment is more effective in terms of clin-
ical, and safety outcomes. Alongside resource utilization and cost of care data, this
evidence can be used to populate cost-effectiveness and other health economic
analyses to inform physician and payer decision-making.
PRM5
VALIDITY OF REQUIRING A MINIMUM DURATION OF POST-INDEX
ENROLLMENT IN RETROSPECTIVE DATABASE STUDIES
Lanes SF
United BioSource Corporation, Lexington , MA, USA
OBJECTIVES: Retrospective database studies commonly use an inclusion criterion
requiring that subjects have a minimum duration of post-index enrollment (i.e.,
follow-up). Such a criterion can simplify analysis and facilitate computation of
annual costs. In clinical trials, however, similar strategies, such as analyses re-
stricted to subjects who completed follow-up (“complete case analysis”), are seen
as problematic because reasons for discontinuation may be related to study end-
points (i.e., informative censoring). METHODS: We reviewed methodologic litera-
ture and we used a health insurance claims database to evaluate the impact on
health care utilization and costs of excluding subjects lost to follow-up. RESULTS:
Excluding from analysis subjects with incomplete follow-up may be valid if pa-
tients aremissing at random. Unfortunately, this assumption can rarely be verified
because endpoints are usually unknown for patients who are lost to follow-up. In
an insurance claims database, an inclusion criterion requiring one year of fol-
low-up decreased health care utilization and average annual costs by 8% for a
random sample of subjects, and by 17% among subjects with a serious illness.
CONCLUSIONS: Subjects are lost to follow-up in both clinical trials and retrospec-
tive database studies (e.g., by exiting the database). Study populations should not
be defined in such a way as to exclude subjects lost to follow-up; instead, subjects
lost to follow-up should be considered as a missing data problem. In retrospective
database studies, just as in clinical trials, if endpoints among subjects lost to fol-
low-up differ from endpoints among subjects remaining in the database, restrict-
ing analysis to patientswithminimumdurations of follow-up candistort outcomes
and economic evaluations. Subjects lost to follow-up in automated databases
should be described and evaluated for evidence of informative censoring, and an-
alyzed using strategies appropriate for missing data, such as multiple imputation
methods.
PRM6
ARE YOU COUNTING PRESCRIPTION MEDICATIONS UTILIZATION CORRECTLY?
Athavale AS1, Banahan BFI1, Hardwick SP2, Clark JP2
1University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS,
USA
OBJECTIVES: To evaluate the potential for duplicate counting of prescriptionmed-
ication utilization for products that are billed through medical and prescription
claims. METHODS: A retrospective cross-sectional descriptive study was con-
ducted using the 2008 – 2011 Mississippi Medicaid data. Medical claims (MCs) with
J-codes for injectable medications were identified from MC files. Prescription
claims (PCs) for the corresponding beneficiaries were extracted from PC data for all
NDCs associated with the J-codes identified. These two sets of claims were stacked
to obtain a denominator file. Potential duplicate counts were identified by pairing
MCs and PCs for the same beneficiary and drug where the PC service date was
within 7 days of the MC service date. The Medicare maximum allowable cost was
identified for the J-code in each potential duplicate count situation. Criteria of the
MC being 80%of themaximumallowable cost for one J-code unit and theMC paid
amount being 80% of the corresponding PC paid amount were used to evaluate
which pairs might be actual duplicate counts. RESULTS: Out of 1,813,251 claims
identified in the denominator file, 1443 drug eventswere considered to be potential
duplicate counts (0.08%). These claims were associated with 849 Medicaid enroll-
ees. For 89%of the pairs, theMCpaid amountwas 80%of the allowable J-code unit
cost and 37% were 80% of the corresponding PC paid amount. Using a combina-
tion of these criteria, it was estimated that at least 47% of the pairs were likely to be
duplicate counts and that a large portion of the other pairs might be duplicate
counts. CONCLUSIONS: Researchers need to use caution when counting medica-
tion events for products reimbursed as MCs and PCs. The error from over-counting
at the population level should be small, but could have significant impact on utili-
zation and adherence estimates for individual patients.
PRM7
A REVIEW AND APPLIED COMPARISON OF META-ANALYSIS TECHNIQUES
Lewis-Beck C1, Baser E2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Istanbul, Turkey,
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
BACKGROUND: Numerous assumptions and techniques are associated with per-
forming meta-analysis. While some overall structural guidelines and recom-
mended practices exist, there are very few papers that compare meta-analysis
techniques in application.OBJECTIVES: To review primarymeta-analysismethods
and their assumptions, and apply various meta techniques to data and compare
the results. METHODS: There are currently a myriad of meta-analysis techniques
available. We started the study with a review of fixed effects models, which is the
most basic technique that assumes homogeneity in treatment effect across stud-
ies. We then explored random effect models and meta regression. Each of these
techniques models treatment heterogeneity. Other more advanced techniques ex-
amined included mixed treatment comparisons (MTC) and Bayesian approaches.
RESULTS: Estimates of treatment effect differed depending on themeta technique
applied. When a fixed effect model was applied to estimate the effect of a vaccina-
tion against tuberculosis, the log odds ratio was -0.436 (confidence interval [CI:
-0.528, -0.344]). After testing for heterogeneity and fitting a random effects model,
the estimate was reduced to -0.741 (CI [-1.12, -0.352]), and the CI became wider.
When covariates were added to the model to explain the heterogeneity, the treat-
ment effect was reduced even further. Additional techniques were applied as well,
such as BayesianMTC. CONCLUSIONS: Results frommeta-analysis are sensitive to
the studies selected, in addition to themethodology applied. To ensure that proper
techniques are used, it is critical to estimate an unbiased outcome.
RESEARCH ON METHODS – COST METHODS
PRM8
GENERAL TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS
Carswell C, McWilliams P, Williamson KA, Faulds D
Adis, Auckland, New Zealand
OBJECTIVES: Economic evaluations of drug therapy are important, but time con-
suming and costly. Analyses that are easily transferable (i.e. adjustable to a differ-
ent jurisdiction without completely rebuilding the model) may potentially save
time and resources. We aimed to develop a tool to assess and summarize the
general transferability ofmodel-based analyses.METHODS:Medline was searched
for literature on transferability published between 2002 and June 2011. Existing
checklists for economic evaluations were adapted to create a checklist of 16 key
factors to assess the general transferability of model-based analyses. This tool was
used to score 11 recently published economic evaluations and identify how well
specific factors were addressed. RESULTS: Transferability scores of the selected
papers ranged from 53–91%, illustrating the wide variability in the quality of re-
porting. Across all studies, the least well addressed transferability factors included
the discussion of the generalizability of the study results (lacking or incomplete in
all studies), adequate description of resources and costs employed in the analysis
(particularly separate reporting of resource use and unit costs), and adequate de-
scriptions of the method and/or populations used to derive utility values. The best
addressed transferability factors included those relating to country, currency and
discount rates. Even if studies scored highly overall, it may still be difficult to
transfer the findings to a different setting if they failed to report insufficient detail
on one or two key parameters. CONCLUSIONS: The general transferability of a
model-based economic evaluation from one country or jurisdiction to another can
be quickly assessed by the application of a simple checklist of key transferability
factors. It is important that authors ensure that they report their economic analysis
in a detailed and transparent fashion.
PRM9
RELEVANCE AND QUALITY OF THE PHARMACOECONOMIC LITERATURE OF FDA
RECENTLY APPROVED DRUGS: A SYSTEMATIC REVIEW
Woersching AL, Raisch DW, Borrego M
University of New Mexico College of Pharmacy, Albuquerque, NM, USA
OBJECTIVES: To perform a systematic literature review of pharmacoeconomic (PE)
publications considering recent United States (US) Food and Drug Administration
(FDA) new molecular entity and new biologic license approvals (NMEs/NBLs). The
review investigated publication quality and US relevance. METHODS: MEDLINE
and the United Kingdom National Health Service Economic Evaluation Database
were searched. Included publications considered 2008-2009 NMEs/NBLs in original
PE evaluations. In addition to general characteristics, each publication was evalu-
ated using the Quality of Health Economic Studies (QHES) Instrument. The corre-
lation between QHES scores and the 2010 Thomson Reuters five-year journal Im-
pact Factor (IF-5y) was calculated. Median QHES score differences were compared
(Mann-Whitney U) by study characteristics (yes/no): US context, academic first
author, pharmaceutical manufacturer funding (PMF), and declared author
independence. RESULTS: From 115 unique search results, 31met inclusion criteria.
Of fifty 2008-2009 NMEs/NBLs, 36% had PE publications, with 81% considering the
approval indication and 61% published post-approval. A US context was assessed
in 35% of publications. PMF was present in 68% of publications, comprising man-
ufacturers marketing either the NME/NBL, 90%, or a comparator, 10%. Time
(meanstandard deviation (S.D.)) since FDA approval was 21.98.8 months until
ePublication and 15.39.0 months until journal submission. Median and
meanS.D. QHES score were 78 and 73.316.4, respectively. Publications most
often satisfied QHES items regarding uncertainty (5) and incremental analysis (6)
(94% each). Justifiying the chosen model (13) and discussing biases (14) were satis-
fied least often (38% each). The IF-5y (mean 3.46, S.D. 3.37) was not correlated
with QHES score (Pearson r0.095, p0.636). QHES scores were not-significantly
different (p0.05) for any study characteristics. CONCLUSIONS: QHES scores indi-
cate PE studies of recent NMEs/NBLs are high quality, although US relevance is
imperfect: few publications assessed a US context; some did not consider the ap-
proval indication; publication lags delay PE evidence availability; and most publi-
cations have PMF.
PRM10
THE BEHAVIORAL ECONOMICS OF THE MINIMALLY IMPORTANT DIFFERENCE
Suh JK, Doctor J
USC School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: To study whether theminimally important differences (MIDs) values
outcomes based on the behavioral economic theory. METHODS: We studied the
behavior of individuals discriminating minimally important differences (MIDs), a
method that identifies the change in a health measure necessary for a patient to
discriminate an improvement. The behavioral theory predicts that discrimination
of a quantity is governed byWeber’s Law: If a quantity is increased by some factor,
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